Biotech Manufacturers to Develop Better Nucleic Acid Sample Preparation Protocols
|
By LabMedica International staff writers Posted on 02 Nov 2014 |
Manufacturers of biotech equipment and reagents are cooperating to ease and simplify protocols for preparing samples to be analyzed by advanced next generation sequencing platforms.
The success of techniques such as next-generation sequencing, microarrays, and library construction is contingent upon the precise and accurate processing of DNA and RNA. Library preparation of nucleic acids relies on a coordinated series of standard molecular biology reactions, and preparation of high quality libraries at high yield is a critical first step in the next generation sequencing workflow. The necessity for improved reagents and protocols for library preparation is growing in parallel with the increase in the number of applications for next generation sequencing.
To develop these new protocols, the instrument manufacturer Beckman Coulter Life Sciences (Nyon, Switzerland) will be collaborating with the reagent manufacturer New England Biolabs, Inc. (Ipswich, MA, USA). Beckman Coulter produces advanced automated liquid handling systems such as the Biomek 4000. New England Biolabs manufactures a line of highly pure "NEBNext" reagents that facilitate library preparation of DNA or RNA for downstream applications such as next generation sequencing and expression library construction.
It is planned that Beckman Coulter will use its extensive experience in automated next generation sequencing sample preparation to develop, distribute, and support automation for New England Biolabs' NEBNext sample preparation reagent kits. New England Biolabs will provide technical expertise on the reagents, chemistry, and protocols.
“Beckman Coulter’s focus on providing our next generation sequencing customers a top-notch portfolio of automated sample preparation solutions makes a partnership with New England Biolabs, a world leading provider of quality reagent systems for molecular biology research, a natural fit,” said Alisa Jackson, senior marketing manager, automated genomics solutions at Beckman Coulter. “Our joint collaborations with scientific researchers have already led to the development of high-quality methods demonstrated to improve efficiency, throughput and results for some of the most challenging sample inputs.”
Related Links:
Beckman Coulter Life Sciences
New England Biolabs, Inc.
The success of techniques such as next-generation sequencing, microarrays, and library construction is contingent upon the precise and accurate processing of DNA and RNA. Library preparation of nucleic acids relies on a coordinated series of standard molecular biology reactions, and preparation of high quality libraries at high yield is a critical first step in the next generation sequencing workflow. The necessity for improved reagents and protocols for library preparation is growing in parallel with the increase in the number of applications for next generation sequencing.
To develop these new protocols, the instrument manufacturer Beckman Coulter Life Sciences (Nyon, Switzerland) will be collaborating with the reagent manufacturer New England Biolabs, Inc. (Ipswich, MA, USA). Beckman Coulter produces advanced automated liquid handling systems such as the Biomek 4000. New England Biolabs manufactures a line of highly pure "NEBNext" reagents that facilitate library preparation of DNA or RNA for downstream applications such as next generation sequencing and expression library construction.
It is planned that Beckman Coulter will use its extensive experience in automated next generation sequencing sample preparation to develop, distribute, and support automation for New England Biolabs' NEBNext sample preparation reagent kits. New England Biolabs will provide technical expertise on the reagents, chemistry, and protocols.
“Beckman Coulter’s focus on providing our next generation sequencing customers a top-notch portfolio of automated sample preparation solutions makes a partnership with New England Biolabs, a world leading provider of quality reagent systems for molecular biology research, a natural fit,” said Alisa Jackson, senior marketing manager, automated genomics solutions at Beckman Coulter. “Our joint collaborations with scientific researchers have already led to the development of high-quality methods demonstrated to improve efficiency, throughput and results for some of the most challenging sample inputs.”
Related Links:
Beckman Coulter Life Sciences
New England Biolabs, Inc.
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest BioResearch News
- Gene Variants Linked to Pollution-Exacerbated Asthma
- Single-Cell Analysis Mapping Links Inflammation Response to Acute Myeloid Leukemia
- Study Reveals New Insights into Rare Blood Cancer Development
- New Findings Clarify Molecular Drivers of Rare Small Intestinal Cancer
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
- Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals
- Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk
- Common White Blood Cells Produce Schizophrenia-Linked Protein
- Nanopore Method Captures RNA Folding at Single-Molecule Resolution
- Tumor Microenvironment Marker Linked to Worse Survival in Solid Tumors
- Hidden Immune Gene Defect May Explain Kaposi Sarcoma Susceptibility
- Genetic Markers May Help Predict Amputation Risk in Peripheral Artery Disease
- Gene Signature Shows Promise for Depression Biomarker Testing
- AI-Driven Tumor Profiling Initiative Targets Precision Therapy Development
Channels
Clinical Chemistry
view channel
FDA-Approved Test Identifies Low Risk of Large Esophageal Varices in Cirrhosis
Chronic liver disease contributes substantially to mortality, and clinicians routinely screen adults with compensated cirrhosis for varices to prevent bleeding. However, endoscopy is invasive and reso... Read more
Blood Protein Signature Diagnoses Pediatric IBD and Distinguishes Subtypes
Confirming pediatric inflammatory bowel disease (IBD) often requires imaging, endoscopy, and histopathology, prolonging time to diagnosis. Reliable, noninvasive blood tests remain an unmet need in routine... Read moreMolecular Diagnostics
view channel
Blood Test Reveals Hidden Pancreatic Cancer After Treatment
Pancreatic cancer often returns even after chemotherapy and surgery, while microscopic disease can remain difficult to detect during surveillance. Standard imaging and broad-panel liquid biopsy tests may... Read more
Model Predicts Increased ALS Clinic Visits with Expanded Genetic Testing
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that rapidly impairs motor function and shortens survival, creating sustained demand for multidisciplinary care.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention
Health systems increasingly rely on economic evidence to guide cancer prevention strategies. For gastric cancer, selecting screening approaches that can integrate with existing programs is a key policy question.... Read more
Machine Learning Reveals Consistent Gut Microbiome Patterns in Colorectal Cancer
Colorectal cancer has been repeatedly linked to alterations in the gut microbiome, yet findings have often varied across small, heterogeneous studies. Reproducibility has been limited by differing sequencing... Read morePathology
view channel
Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
Reliable histologic subtyping guides therapy selection in oncology, yet diagnostic workflows grow more complex as whole-slide imaging and artificial intelligence (AI) expand. A persistent obstacle to clinical... Read more
Study Highlights Biomarker Testing Delays in Lung Cancer Care
Timely biomarker results are critical to match lung cancer patients with targeted therapies or immunotherapies, yet many clinical pathways still delay testing after biopsy. Ordering responsibility, reimbursement... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel









